178 related articles for article (PubMed ID: 9731065)
41. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
42. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.
Runge MS; Quertermous T; Zavodny PJ; Love TW; Bode C; Freitag M; Shaw SY; Huang PL; Chou CC; Mullins D
Proc Natl Acad Sci U S A; 1991 Nov; 88(22):10337-41. PubMed ID: 1946453
[TBL] [Abstract][Full Text] [Related]
43. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP).
Roemisch J; Feussner A; Nerlich C; Stoehr HA; Weimer T
Blood Coagul Fibrinolysis; 2002 Jul; 13(5):433-41. PubMed ID: 12138371
[TBL] [Abstract][Full Text] [Related]
44. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
45. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.
Simon DI; Rao NK; Xu H; Wei Y; Majdic O; Ronne E; Kobzik L; Chapman HA
Blood; 1996 Oct; 88(8):3185-94. PubMed ID: 8874219
[TBL] [Abstract][Full Text] [Related]
46. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
47. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
Pannell R; Kung W; Gurewich V
J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
[TBL] [Abstract][Full Text] [Related]
48. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
49. The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator.
Lubin IM; Caban R; Runge MS
J Biol Chem; 1993 Mar; 268(8):5550-6. PubMed ID: 8449917
[TBL] [Abstract][Full Text] [Related]
50. Regulation of single chain urokinase by small peptides.
Higazi A al-R ; Cines D
Thromb Res; 1996 Nov; 84(4):243-52. PubMed ID: 8948049
[TBL] [Abstract][Full Text] [Related]
51. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
52. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
53. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
[TBL] [Abstract][Full Text] [Related]
54. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
55. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
56. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
[TBL] [Abstract][Full Text] [Related]
57. Remaining perspectives of mutant and chimeric plasminogen activators.
Lijnen HR; Collen D
Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
[TBL] [Abstract][Full Text] [Related]
58. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors.
Kirchheimer JC; Remold HG
Blood; 1989 Sep; 74(4):1396-402. PubMed ID: 2548640
[TBL] [Abstract][Full Text] [Related]
59. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
60. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Idell S
Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
